SCHEMBL18873374

SCHEMBL18873374

Cc1ccc(C)c(/C=N/Nc2nc3ccccc3s2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 17/20 0.61
▸ KMT2A Q03164 12/20 0.61
▸ RAB9A P51151 12/20 0.61
▸ MEN1 O00255 11/20 0.61
▸ NPC1 O15118 11/20 0.61
▸ GAA P10253 10/20 0.61
▸ SMN1; SMN2 Q16637 10/20 0.61
▸ NFKB1 P19838 5/20 0.61
▸ NFKB2 Q00653 5/20 0.61
▸ RELA Q04206 5/20 0.61
▸ GLA P06280 1/20 0.61
▸ HPGD P15428 1/20 0.61
▸ ALOX12 P18054 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ CYP1A2 P05177 1/20 0.61
▸ HSP90AA1 P07900 1/20 0.61
▸ CYP2D6 P10635 1/20 0.61
▸ CYP2C9 P11712 1/20 0.61
▸ CYP2C19 P33261 1/20 0.61
▸ LMNA P02545 7/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17696370 0.88 MAPT (0.57) MAPTKMT2ARAB9AMEN1NPC1
SCHEMBL17696367 0.86 MAPT (0.57) MAPTKMT2ARAB9AMEN1NPC1
SCHEMBL18873384 0.80 GAA (0.48) MAPTKMT2ARAB9AMEN1NPC1
SCHEMBL22103769 0.78 MAPT (0.64) MAPTKMT2ARAB9AMEN1NPC1
SCHEMBL1132583 0.76 MAPT (0.58) MAPTKMT2ARAB9AMEN1NPC1
SCHEMBL1132582 0.76 MAPT (0.58) MAPTKMT2ARAB9AMEN1NPC1
SCHEMBL18873378 0.76 KMT2A (0.44) MAPTKMT2ARAB9AMEN1NPC1
SCHEMBL1231354 0.76 MAPT (0.70) MAPTKMT2ARAB9AMEN1NPC1
SCHEMBL1231353 0.76 MAPT (0.70) MAPTKMT2ARAB9AMEN1NPC1
SCHEMBL17123531 0.75 MAPT (0.67) MAPTKMT2ARAB9AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212136-A1 CURABLE RESIN COMPOSITION, CURED PRODUCT, DIFFRACTIVE OPTICAL ELEMENT, AND MULTILAYER DIFFRACTIVE OPTICAL ELEMENT FUJIFILM CORPORATION (JP) 2023-07-06 — — US disclosed
US-11370740-B2 Method for producing ester group-containing compound DIC CORPORATION (JP) 2022-06-28 — — US disclosed
US-20220162505-A1 Polymerizable LC Material and Polymer Film MERCK PATENT GMBH (DE) 2022-05-26 — — US disclosed
US-11046889-B2 Polymerizable compound and optically anisotropic body DIC CORPORATION (JP) 2021-06-29 — — US disclosed
US-10919870-B2 Polymerizable compound and optically anisotropic body DIC CORPORATION (JP) 2021-02-16 — — US disclosed
US-20200362245-A1 POLYMERISABLE LC MEDIUM AND POLYMER FILM WITH FLAT OPTICAL DISPERSION MERCK PATENT GMBH (DE) 2020-11-19 — — US disclosed
US-20200199453-A1 POLYMERISABLE LIQUID CRYSTAL MATERIAL AND POLYMERISED LIQUID CRYSTAL FILM MERCK PATENT GMBH (DE) 2020-06-25 — — US disclosed
US-10649124-B2 Composition including compound having mesogenic group, polymer and optically anisotropic body obtained by polymerizing polymerizable composition, and phase difference film DIC CORPORATION (JP) 2020-05-12 — — US disclosed
US-20190025490-A1 COMPOSITION INCLUDING COMPOUND HAVING MESOGENIC GROUP, POLYMER AND OPTICALLY ANISOTROPIC BODY OBTAINED BY POLYMERIZING POLYMERIZABLE COMPOSITION, AND PHASE DIFFERENCE FILM DIC CORPORATION (JP) 2019-01-24 — — US disclosed
EP-3346304-A1 COMPOSITION INCLUDING COMPOUND HAVING MESOGENIC GROUP, POLYMER AND OPTICALLY ANISOTROPIC BODY OBTAINED BY POLYMERIZING POLYMERIZABLE COMPOSITION, AND PHASE DIFFERENCE FILM DIC Corporation (JP) 2018-07-11 — — EP disclosed
WO-2017079867-A1 POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY DIC CORPORATION (JP) 2017-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11370740-B2 Method for producing ester group-containing compound COASY, TAF5, TAF9 MAPT 782/4885KMT2A 3193/4885RAB9A 2782/4885
US-10919870-B2 Polymerizable compound and optically anisotropic body ZYX, ZW10, DPY30 MAPT 545/4885KMT2A 2769/4885RAB9A 1874/4885
US-20230212136-A1 CURABLE RESIN COMPOSITION, CURED PRODUCT, DIFFRACTIVE OPTICAL ELEMENT, AND MULTILAYER DIFFRACTIVE OPTICAL ELEMENT TERB1, RER1, LARP1 MAPT 655/4885KMT2A 2248/4885RAB9A 2669/4885
US-11046889-B2 Polymerizable compound and optically anisotropic body OCIAD1, RCC1, OCIAD2 MAPT 323/4885KMT2A 4308/4885RAB9A 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback